

## State of Oklahoma Oklahoma Health Care Authority Xtandi<sup>®</sup> (Enzalutamide) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:	) Start Date	(or date of next dose):
Dose:	Regimen:	
	Billing Provider Informa	ation
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fa	ах:
	Prescriber Informati	on
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
<ol> <li>Is diagnosis castration</li> <li>Is diagnosis metastati</li> </ol>	on (Initial approval will be for n-resistant prostate cancer (CRP) c castration-sensitive prostate ca ne above, please indicate diagnos	C)? Yes No
For Continued Author		
Yes No 3. Has the member experience Yes No	y evidence of progressive disease	e while on enzalutamide therapy? ons related to enzalutamide therapy?
Additional Information:		
I certify that the indicated	I treatment is medically necessary	Date:y and all information is true and
	knowledge. t notes. Specific information will be i ill result in processing delays.	requested if necessary. Failure to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.